These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35204078)

  • 1. Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection.
    Cha SJ; Kim K
    Antioxidants (Basel); 2022 Jan; 11(2):. PubMed ID: 35204078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edaravone: a new hope for deadly amyotrophic lateral sclerosis.
    Bhandari R; Kuhad A; Kuhad A
    Drugs Today (Barc); 2018 Jun; 54(6):349-360. PubMed ID: 29998226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Edaravone for the treatment of amyotrophic lateral sclerosis.
    Yoshino H
    Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
    Watanabe K; Tanaka M; Yuki S; Hirai M; Yamamoto Y
    J Clin Biochem Nutr; 2018 Jan; 62(1):20-38. PubMed ID: 29371752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
    Park JM; Kim SY; Park D; Park JS
    Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis.
    Okada M; Yamashita S; Ueyama H; Ishizaki M; Maeda Y; Ando Y
    eNeurologicalSci; 2018 Jun; 11():11-14. PubMed ID: 29928711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis.
    Cho H; Shukla S
    Pharmaceuticals (Basel); 2020 Dec; 14(1):. PubMed ID: 33396271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury.
    Shakkour Z; Issa H; Ismail H; Ashekyan O; Habashy KJ; Nasrallah L; Jourdi H; Hamade E; Mondello S; Sabra M; Zibara K; Kobeissy F
    Curr Med Chem; 2021; 28(12):2369-2391. PubMed ID: 32787753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edaravone, a scavenger for multiple reactive oxygen species, reacts with singlet oxygen to yield 2-oxo-3-(phenylhydrazono)-butanoic acid.
    Amekura S; Shiozawa K; Kiryu C; Yamamoto Y; Fujisawa A
    J Clin Biochem Nutr; 2022 May; 70(3):240-247. PubMed ID: 35692681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
    Jaiswal MK
    Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing.
    Soejima-Kusunoki A; Okada K; Saito R; Watabe K
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients.
    Ohta Y; Yamashita T; Nomura E; Hishikawa N; Ikegami K; Osakada Y; Matsumoto N; Kawahara Y; Yunoki T; Takahashi Y; Takamiya M; Tadokoro K; Sasaki R; Nakano Y; Tsunoda K; Sato K; Omote Y; Takemoto M; Abe K
    J Neurol Sci; 2020 Aug; 415():116906. PubMed ID: 32446009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion.
    Brooks BR; Jorgenson JA; Newhouse BJ; Shefner JM; Agnese W
    Am J Manag Care; 2018 Apr; 24(9 Suppl):S175-S186. PubMed ID: 29693363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edaravone, a Free Radical Scavenger, Delayed Symptomatic and Pathological Progression of Motor Neuron Disease in the Wobbler Mouse.
    Ikeda K; Iwasaki Y
    PLoS One; 2015; 10(10):e0140316. PubMed ID: 26469273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis.
    Ohta Y; Nomura E; Shang J; Feng T; Huang Y; Liu X; Shi X; Nakano Y; Hishikawa N; Sato K; Takemoto M; Yamashita T; Abe K
    J Neurosci Res; 2019 May; 97(5):607-619. PubMed ID: 30565312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration.
    Nagase M; Yamamoto Y; Miyazaki Y; Yoshino H
    Redox Rep; 2016 May; 21(3):104-12. PubMed ID: 26191780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edaravone and its clinical development for amyotrophic lateral sclerosis.
    Takei K; Watanabe K; Yuki S; Akimoto M; Sakata T; Palumbo J
    Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):5-10. PubMed ID: 28872907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edaravone decreases paraquat toxicity in a549 cells and lung isolated mitochondria.
    Shokrzadeh M; Shaki F; Mohammadi E; Rezagholizadeh N; Ebrahimi F
    Iran J Pharm Res; 2014; 13(2):675-81. PubMed ID: 25237364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis.
    Terada T; Kulkarni JA; Huynh A; Tam YYC; Cullis P
    Biol Pharm Bull; 2021; 44(1):144-149. PubMed ID: 33390543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
    Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
    J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.